Cephamycin resistance in clinical isolates and laboratory-derived strains of Escherichia coli, Nova Scotia, Canada.
Clarke
Brian
B
Division of Microbiology, Dalhousie University and the Queen Elizabeth II Health Sciences Centre, 5788 University Avenue, Halifax, Nova Scotia B3H 1V8, Canada.
Hiltz
Margot
M
Musgrave
Heather
H
Forward
Kevin R
KR
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001483:Base Sequence; D002440:Cefoxitin / Q000494:pharmacology; D002513:Cephamycins / Q000494:pharmacology*; D004269:DNA, Bacterial / Q000235:genetics; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D004926:Escherichia coli / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification*; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology; D029968:Escherichia coli Proteins / Q000235:genetics; D005798:Genes, Bacterial; D006801:Humans; D066298:In Vitro Techniques; D008969:Molecular Sequence Data; D009154:Mutation; D009674:Nova Scotia; D018272:Porins / Q000235:genetics; D011401:Promoter Regions, Genetic; D018440:beta-Lactam Resistance / Q000235:genetics
D000900:Anti-Bacterial Agents; D002513:Cephamycins; D004269:DNA, Bacterial; D029968:Escherichia coli Proteins; C113724:OmpC protein; C109237:OmpF protein; D018272:Porins; D002440:Cefoxitin